Telix Pharmaceuticals reports Q1 results; reaffirms FY25 outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 22 2025
0mins
Source: SeekingAlpha
Q1 Revenue Growth: Telix Pharmaceuticals reported a Q1 revenue of $186 million, marking a 62% increase from the same quarter last year and a 31% rise from the previous quarter.
FY 2025 Guidance: The company reaffirmed its FY 2025 revenue guidance of $770 million to $800 million, while also indicating an expected 20% to 25% increase in R&D expenditures compared to FY 2024.
Analyst Views on TLX
About TLX
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
